Abstract
After liver transplantation, reinfection of the newly engrafted liver with hepatitis C virus is essentially universal in patients who are viremic at the time of transplantation. Treatment with interferon preparations with or without ribavirin is recommended in patients with marked histologic injury; however, hematologic toxicity associated with therapy has been reported, which is usually treated with growth factor support, including erythropoietin analogues. We present the first reported case of antierythropoietin antibody-mediated pure red cell aplasia arising in the setting of hepatitis C virus therapy in a patient who underwent living donor liver transplantation.
Original language | English (US) |
---|---|
Pages (from-to) | 1589-1592 |
Number of pages | 4 |
Journal | Liver Transplantation |
Volume | 13 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2007 |
Externally published | Yes |
ASJC Scopus subject areas
- Surgery
- Hepatology
- Transplantation